ReviewThe Lancet regional health. Europe2026
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.
Review in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reply to 'Closing the policy gap: including children in the global agenda for steatotic liver disease'.Nature reviews. Gastroenterology & hepatology · 2026Article
- A global commitment to addressing chronic liver disease.The Lancet regional health. Europe · 2026Article
- Closing the Implementation Gap: New Models of Care to End Chronic Liver Disease.The Lancet regional health. Europe · 2026Article
Corrections and comments
- Commented on by
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steatotic liver disease (SLD) is the leading cause of chronic liver disease in Europe, with liver fibrosis representing the strongest predictor of liver-related outcomes and an important contributor to cardiometabolic risk. This Series paper examines diagnostic innovation and models of care to improve fibrosis detection and risk stratification across the continuum of care for SLD. A growing range of non-invasive tests for fibrosis assessment is now available, including blood-based biomarkers, imaging modalities, automated laboratory algorithms, and artificial intelligence-enabled tools. However, implementation remains inconsistent because of limited awareness, restricted geographic and financial access to advanced diagnostics, fragmented referral pathways, heterogeneous reimbursement, limited use of automated reflex testing, and poor digital integration across laboratories and electronic health records. Integrated multidisciplinary models of care linking primary care with specialist services may improve early fibrosis detection, referral efficiency, and equitable access to risk-stratified management, particularly among people living with indicator conditions such as type 2 diabetes and obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.